• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Medications to Treat OCD

Medications to Treat OCD

June 22, 2013
Jessica L. Goren, PharmD, BCPP

While most patients with obsessive-compulsive disorder (OCD) can derive benefit from psychopharmacologic treatment, cognitive behavioral therapy (CBT) that includes exposure and response prevention is recommended without pharmacotherapy when feasible (American Psychiatric Association (APA). Practice guideline for the treatment of patients with obsessive-compulsive disorder. Arlington, VA: 2007. www.psychiatryonline.org).



For patients who prefer medication only, do not have access to CBT, or have severe OCD (or other severe mental conditions) that would benefit from decreased symptoms prior to starting CBT, psychopharmacologic monotherapy is a reasonable treatment option (APA practice guideline op.cit).



The mainstays of treatment for OCD are the selective serotonin reuptake inhibitors (SSRIs). Currently, the following SSRIs are approved for the treatment of OCD in the US. They are:




  • Fluoxetine (Prozac)

  • Fluvoxamine (Luvox)

  • Paroxetine (Paxil, Pexeva)

  • Sertraline (Zoloft)



While other SSRIs are not approved for the treatment of OCD, they are most likely also effective. Clomipramine (Anafranil), a tricyclic antidepressant (TCA), has significant serotonin reuptake inhibition properties and is also approved in the US for the treatment of OCD.



 




Table 1: Medications to Treat OCD

Click here to open pdf


 



Data indicate that SSRIs are superior to placebo in both pediatric and adult populations with a moderate effect size (0.46 CI 0.37–0.55 and 0.48 CI 0.36–0.61, respectively) (Soomro GM et al, Cochrane Database Syst Rev 2008;1:CD001765). Most meta-analyses report clomipramine (Anafranil) is superior to SSRIs in adults and pediatric patients (see for example Watson HJ and Rees CS, J Child Psychol Psychiatry 2008;49(5):489–498). However, given the side effect profile of the TCAs, clomipramine is typically reserved for patients who have failed SSRI treatment (APA practice guideline ibid).



Most patients experience a significant improvement in symptoms, but psychopharmacologic interventions rarely lead to complete remission of symptoms. Data indicate that achieving at least a 25% reduction in symptoms is almost twice as likely with SSRI treatment than with placebo. Regardless of which medication is prescribed, most patients will not experience substantial improvement in symptoms until a minimum of four to six weeks after starting and some may not experience symptom improvement until as many as 10 to 12 weeks after starting (APA practice guideline ibid).



Adverse effects of SSRIs include mild gastrointestinal effects; anxiety, agitation and insomnia (particularly when initiating treatment); bleeding (especially in those on NSAIDs or anticoagulants); sexual dysfunction; weight gain (predominately paroxetine); and QTc prolongation (most recently associated with doses of citalopram greater than 40 mg daily). Clomipramine use is limited by anticholinergic and sexual side effects as well as dose-related seizures and cardiac toxicity.



Other Pharmacological Treatments



For patients who do not respond to the first psychopharmacologic treatment, it is important to ensure comorbid psychiatric illnesses are treated, the patient has had an adequate trial of the maximum recommended or tolerated dose of the medication, and has been adherent with treatment. For those who do not experience significant relief after these interventions, you should consider the addition of CBT, switching to a different SSRI, or use of clomipramine.



Patients who have failed multiple adequate trials of SSRIs, clomipramine, and CBT may benefit from augmentation strategies (APA practice guideline ibid; Lewin AB et al, Neuropsychiatr Dis Treat 2006;2(1):21–31). These augmentation strategies include pro-serotonergic agents (eg, buspirone, lithium), antipsychotics, and benzodiazepines. The best evidence exists for antipsychotics, particularly second generation antipsychotics such as aripiprazole (Abilify) or risperidone (Risperdal) (Ipser JC et al. Cochrane Database of Syst Rev 2006;4:CD005473; APA practice guideline ibid).



Ondansetron (Zofran), memantine (Namenda), riluzole (Rilutek), clomipramine, and mirtazapine (Remeron) have preliminary evidence to suggest benefit as augmentation of SSRIs for refractory OCD (APA practice guideline ibid; Abdel-Ahad P et al, Curr Clin Pharmacol 2013 Feb 4;online ahead of print).



While open-label studies support the use of lithium augmentation of SSRIs, controlled trials have not demonstrated benefit with the combination. Data with buspirone augmentation have been mixed. Therefore, use of buspirone and lithium augmentation should be reserved for patients with comorbidities responsive to these agents or those who have failed other treatments.



Antipsychotics have been shown to be beneficial as augmentation for SSRIs in randomized controlled trials. Placebo controlled trials of antipsychotics have found significantly higher response rates compared with placebo (46% to 71%) and relapse rates of more than 80% when antipsychotics are discontinued in responders.



Benzodiazepines have not been consistently shown to be of benefit for OCD as monotherapy or augmentation. In addition, their use is limited by sedation, motor side effects, and potential for disinhibition. However, given their quick onset of action, they may play a role in decreasing anxiety associated with initiation of SSRIs (APA practice guideline, Abdel-Ahad ibid).



Non-Pharmacologic Treatments



Other non-pharmacologic treatments that show promise for OCD include neurosurgery, deep brain stimulation, electroconvulsive therapy (ECT), and transcranial magnetic stimulation.



Given the risk associated with neurosurgery, this treatment is typically reserved for those with incapacitating OCD that does not respond to medication and CBT. Anterior cingulotomy, subcaudate tractotomy, and anterior capsulotomy have been shown (in uncontrolled studies) to lead to improvements in 35% to 70% of patients with refractory OCD and depression.



Deep brain stimulation is a promising treatment but current data are limited. In a randomized controlled trial, right bilateral prefrontal transcranial magnetic stimulation resulted in up to a 35% decrease in symptoms compared with a 6.2% decrease with sham treatment (Gomes PV et al, J Neuropsychiatry Clin Neurosci 2012;24(4):437–443). ECT has traditionally been reserved for those with comorbid depression and OCD, and is typically not used for OCD alone (Arumugham SS and Reddy JY, Expert Rev Neurother 2013;13(2):187–202).



TCRBH’s Take: Pharmacological “treatment response” in research on OCD is typically defined as achieving at least a 25% to 35% reduction of symptoms. Even though that bar is set quite low, that relatively small reduction in symptoms can make the difference between severe impairment and moderate impairment—and it can enable a patient to engage in CBT for OCD who might otherwise have been unable or unwilling to do so.


KEYWORDS ocd
    Carlat Total Access Subscriptions: Get access to every article on the website.

    Complete access to every article you search on the website.

    Shop for Total Access
    Free Psychiatry Updates
    The latest unbiased psychiatric information sent to your inbox.
    Specify Your Interests
    Featured Book
    • HospPsychiatry_Spiral_Binding_Sm.png

      Hospital Psychiatry Fact Book, First Edition (2025) - Spiral Bound

      This comprehensive guide is designed to be a valuable resource for professionals working in...
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.